Tong Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tong Lu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
45 shared publications - Donghui Han
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
44 shared publications - Weihong Wen
School of Life Sciences and Technology Northwestern Polytechnical University Xi'an China
44 shared publications - Weijun Qin
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
44 shared publications - Keying Zhang
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
43 shared publications - Fa Yang
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
42 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes DNMT1 expression
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes DNMT1 expression